Photo of Omid C. Farokhzad,  MD

Omid C. Farokhzad, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-6093
Fax: (617) 730-2801


ofarokhzad@partners.org

Omid C. Farokhzad, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Associate Professor, Anesthesia, Harvard Medical School
  • Director, Laboratory of Nanomedicine and Biomaterials, Anaesthesia, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Omid Farokhzad is an Associate Professor at Harvard Medical School (HMS) and a physician-scientist at Brigham and Women’s Hospital (BWH). Dr. Farokhzad directs the Laboratory of Nanomedicine and Biomaterials at BWH. He is a faculty member of the Brigham Research Institute Cancer Research Center and a member of the Dana Farber/Harvard Cancer Center. Dr. Farokhzad’s research is focused on the development of therapeutic nanoparticle technologies; most notably, he pioneered the high throughput combinatorial development and screening of multifunctional nanoparticles for medical applications. Dr. Farokhzad has authored approximately 110 papers and holds more than 135 issued/pending US and International patents. The technologies that Dr. Farokhzad has developed with collaborators at HMS and MIT have formed the basis for: 1) a new class of targeted nanoparticles for treatment of important human diseases including cancer and cardiovascular disease; 2) a new class of synthetic nanoparticle vaccines for prophylactic and therapeutic applications and 3) a new class of integrative combination nanomedicines for synergistic treatment of cancers, inflammation/pain, and infectious diseases. These technologies formed the foundational platform for the launch of three biotechnology companies: BIND Therapeutics (NASDAQ: BIND), Selecta Biosciences, Blend Therapeutics, which are translating the aforementioned academic innovations toward commercialization and societal impact. Dr. Farokhzad was elected to the College of the Fellows of the American Institute of Medical and biological Engineering. He was a recipient of the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes, for the development and industrialization of nanoparticle technologies for medical applications. In 2013, the Boston Globe selected him among the top innovators in Massachusetts and the Boston Business Journal selected him among the Health Care Champions for his innovations. In 2012, he was among the regional Ernst & Young Entrepreneur of the Year awardees. Dr. Farokhzad completed his post-graduate clinical and post-doctoral research trainings, respectively, at the BWH/HMS and MIT in the laboratory of Institute Professor Robert Langer. He received his M.D. and M.A. from Boston University School of Medicine.

Publications

Powered by Harvard Catalyst
  • Yameen B, Vilos C, Choi WI, Whyte A, Huang J, Pollit L, Farokhzad OC. Drug Delivery Nanocarriers from Fully Degradable PEG-Conjugated Polyester with Reduction-Responsive Backbone. Chemistry 2015. PubMed
  • Wu J, Zhao L, Xu X, Bertrand N, Choi WI, Yameen B, Shi J, Shah V, Mulvale M, MacLean JL, Farokhzad OC. Hydrophobic Cysteine Poly(disulfide)-based Redox-Hypersensitive Nanoparticle Platform for Cancer Theranostics. Angew Chem Int Ed Engl 2015. PubMed
  • Zhu X, Xu Y, Solis LM, Tao W, Wang L, Behrens C, Xu X, Zhao L, Liu D, Wu J, Zhang N, Wistuba II, Farokhzad OC, Zetter BR, Shi J. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A 2015; 112:7779-84. PubMed
  • Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle drug delivery technologies for oral delivery applications. Expert Opin Drug Deliv 2015. PubMed
  • Maldonado RA, LaMothe RA, Ferrari JD, Zhang AH, Rossi RJ, Kolte PN, Griset AP, O'Neil C, Altreuter DH, Browning E, Johnston L, Farokhzad OC, Langer R, Scott DW, von Andrian UH, Kishimoto TK. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci U S A 2015; 112:E156-65. PubMed
  • Saw PE, Park J, Lee E, Ahn S, Lee J, Kim H, Kim J, Choi M, Farokhzad OC, Jon S. Effect of PEG pairing on the efficiency of cancer-targeting liposomes. Theranostics 2015; 5:746-54. PubMed
  • Choi WI, Kamaly N, Riol-Blanco L, Lee IH, Wu J, Swami A, Vilos C, Yameen B, Yu M, Shi J, Tabas I, von Andrian UH, Jon S, Farokhzad OC. A Solvent-Free Thermosponge Nanoparticle Platform for Efficient Delivery of Labile Proteins. Nano Lett 2014. PubMed
  • Pridgen EM, Alexis F, Farokhzad OC. Polymeric nanoparticle technologies for oral drug delivery. Clin Gastroenterol Hepatol 2014; 12:1605-10. PubMed
  • Yameen B, Choi WI, Vilos C, Swami A, Shi J, Farokhzad OC. Insight into nanoparticle cellular uptake and intracellular targeting. J Control Release 2014; 190:485-99. PubMed
  • Wu J, Kamaly N, Shi J, Zhao L, Xiao Z, Hollett G, John R, Ray S, Xu X, Zhang X, Kantoff PW, Farokhzad OC. Development of multinuclear polymeric nanoparticles as robust protein nanocarriers. Angew Chem Int Ed Engl 2014; 53:8975-9. PubMed
  • Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, Roccaro AM, Farokhzad OC, Ghobrial IM. Engineered nanomedicine for myeloma and bone microenvironment targeting. Proc Natl Acad Sci U S A 2014. PubMed
  • Gadde S, Even-Or O, Kamaly N, Hasija A, Gagnon PG, Adusumilli KH, Erakovic A, Pal AK, Zhang XQ, Kolishetti N, Shi J, Fisher EA, Farokhzad OC. Development of Therapeutic Polymeric Nanoparticles for the Resolution of Inflammation. Adv Healthc Mater 2014. PubMed
  • Shi J, Xu Y, Xu X, Zhu X, Pridgen E, Wu J, Votruba AR, Archana S, Zetter BR, Farokhzad OC. Hybrid lipid-polymer nanoparticles for sustained siRNA delivery and gene silencing. 2014. PubMed
  • Ilyinskii PO, Roy CJ, O'Neil CP, Browning EA, Pittet LA, Altreuter DH, Alexis F, Tonti E, Shi J, Basto PA, Iannacone M, Radovic-Moreno AF, Langer RS, Farokhzad OC, von Andrian UH, Johnston LP, Kishimoto TK. Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release. Vaccine 2014. PubMed
  • Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014; 66:2-25. PubMed
  • Lim JM, Bertrand N, Valencia PM, Rhee M, Langer R, Jon S, Farokhzad OC, Karnik R. Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. 2014; 10:401-9. PubMed
  • Valencia PM, Pridgen EM, Rhee M, Langer R, Farokhzad OC, Karnik R. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano 2013; 7:10671-80. PubMed
  • Pridgen EM, Alexis F, Kuo TT, Levy-Nissenbaum E, Karnik R, Blumberg RS, Langer R, Farokhzad OC. Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery. Sci Transl Med 2013; 5:213ra167. PubMed
  • Kim Y, Fay F, Cormode DP, Sanchez-Gaytan BL, Tang J, Hennessy EJ, Ma M, Moore K, Farokhzad OC, Fisher EA, Mulder WJ, Langer R, Fayad ZA. Single step reconstitution of multifunctional high-density lipoprotein-derived nanomaterials using microfluidics. ACS Nano 2013; 7:9975-83. PubMed
  • Xu X, Xie K, Zhang XQ, Pridgen EM, Park GY, Cui DS, Shi J, Wu J, Kantoff PW, Lippard SJ, Langer R, Walker GC, Farokhzad OC. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A 2013; 110:18638-43. PubMed
  • Mieszawska AJ, Kim Y, Gianella A, van Rooy I, Priem B, Labarre MP, Ozcan C, Cormode DP, Petrov A, Langer R, Farokhzad OC, Fayad ZA, Mulder WJ. Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy. Bioconjug Chem 2013; 24:1429-34. PubMed
  • Johnstone TC, Kulak N, Pridgen EM, Farokhzad OC, Langer R, Lippard SJ. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano 2013; 7:5675-83. PubMed
  • Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC. Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology. Cancer Res 2013; 73:2412-2417. PubMed
  • Xiao Z, Ji C, Shi J, Pridgen EM, Frieder J, Wu J, Farokhzad OC. DNA self-assembly of targeted near-infrared-responsive gold nanoparticles for cancer thermo-chemotherapy. Angew Chem Int Ed Engl 2012; 51:11853-7. PubMed
  • Zhao W, Cui CH, Bose S, Guo D, Shen C, Wong WP, Halvorsen K, Farokhzad OC, Teo GS, Phillips JA, Dorfman DM, Karnik R, Karp JM. Bioinspired multivalent DNA network for capture and release of cells. Proc Natl Acad Sci U S A 2012. PubMed
  • Salvador-Morales C, Valencia PM, Gao W, Karnik R, Farokhzad OC. Spontaneous Formation of Heterogeneous Patches on Polymer-Lipid Core-Shell Particle Surfaces during Self-Assembly. Small 2012. PubMed
  • Valencia PM, Pridgen EM, Perea B, Gadde S, Sweeney C, Kantoff PW, Bander NH, Lippard SJ, Langer R, Karnik R, Farokhzad OC. Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomed 2012. PubMed
  • Valencia PM, Farokhzad OC, Karnik R, Langer R. Microfluidic technologies for accelerating the clinical translation of nanoparticles. Nat Nanotechnol 2012; 7:623-9. PubMed
  • Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev 2012; 64:1363-84. PubMed
  • Farokhzad OC. Using ligands to target cancer cells. Clin Adv Hematol Oncol 2012; 10:543-4. PubMed
  • Kim Y, Lee Chung B, Ma M, Mulder WJ, Fayad ZA, Farokhzad OC, Langer R. Mass production and size control of lipid-polymer hybrid nanoparticles through controlled microvortices. Nano Lett 2012; 12:3587-91. PubMed
  • Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A 2011; 108:1850-5. PubMed
  • Gao W, Chan J, Farokhzad OC. pH-responsive Nanoparticles for Drug Delivery. Mol Pharm 2010; 7:1913-20. PubMed
  • Kolishetti N, Dhar S, Valencia PM, Lin LQ, Karnik R, Lippard SJ, Langer R, Farokhzad OC. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci U S A 2010; 107:17939-44. PubMed
  • Shi J, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 2010; 10:3223-30. PubMed
  • Gao W, Langer R, Farokhzad OC. Poly(ethylene glycol) with observable shedding. Angew Chem Int Ed Engl 2010; 49:6567-71. PubMed
  • Wang AZ, Yuet K, Zhang L, Gu FX, Huynh-Le M, Radovic-Moreno AF, Kantoff PW, Bander NH, Langer R, Farokhzad OC. ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomed 2010; 5:361-8. PubMed
  • Valencia PM, Basto PA, Zhang L, Rhee M, Langer R, Farokhzad OC, Karnik R. Single-Step Assembly of Homogenous Lipid-Polymeric and Lipid-Quantum Dot Nanoparticles Enabled by Microfluidic Rapid Mixing. ACS Nano 2010; 4:1671-9. PubMed
  • Chan JM, Zhang L, Tong R, Ghosh D, Gao W, Liao G, Yuet KP, Gray D, Rhee JW, Cheng J, Golomb G, Libby P, Langer R, Farokhzad OC. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc Natl Acad Sci U S A 2010; 107:2213-8. PubMed
  • Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, Shi J, Kuritzkes DR, Langer R, von Andrian U, Farokhzad OC. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomed 2010; 5:269-85. PubMed
  • Chan JM, Valencia PM, Zhang L, Langer R, Farokhzad OC. Polymeric nanoparticles for drug delivery. Methods Mol Biol 2010; 624:163-75. PubMed
  • Gao W, Xiao Z, Radovic-Moreno A, Shi J, Langer R, Farokhzad OC. Progress in siRNA delivery using multifunctional nanoparticles. Methods Mol Biol 2010; 629:53-67. PubMed
  • Alexis F, Pridgen EM, Langer R, Farokhzad OC. Nanoparticle technologies for cancer therapy. Handb Exp Pharmacol 2010. PubMed
  • Salvador-Morales C,Zhang L,Langer R,Farokhzad OC. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009; 30:2231-40. PubMed
  • Chan JM,Zhang L,Yuet KP,Liao G,Rhee JW,Langer R,Farokhzad OC. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2008; 30:1627-34. PubMed
  • Salvador-Morales C,Gao W,Ghatalia P,Murshed F,Aizu W,Langer R,Farokhzad OC. Multifunctional nanoparticles for prostate cancer therapy. Expert Rev Anticancer Ther 2009; 9:211-21. PubMed
  • Farokhzad OC,Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3:16-20. PubMed
  • Gu F,Langer R,Farokhzad OC. Formulation/Preparation of functionalized nanoparticles for in vivo targeted drug delivery. Methods Mol Biol 2009; 544:589-98. PubMed
  • Alexis F,Basto P,Levy-Nissenbaum E,Radovic-Moreno AF,Zhang L,Pridgen E,Wang AZ,Marein SL,Westerhof K,Molnar LK,Farokhzad OC. HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy. ChemMedChem 2008; 3:1839-43. PubMed
  • Dhar S,Gu FX,Langer R,Farokhzad OC,Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A 2008; 105:17356-61. PubMed
  • Wang AZ,Bagalkot V,Vasilliou CC,Gu F,Alexis F,Zhang L,Shaikh M,Yuet K,Cima MJ,Langer R,Kantoff PW,Bander NH,Jon S,Farokhzad OC. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008; 3:1311-5. PubMed
  • Farokhzad OC. Nanotechnology for drug delivery: the perfect partnership. Expert Opin Drug Deliv 2008; 5:927-9. PubMed
  • Karnik R,Gu F,Basto P,Cannizzaro C,Dean L,Kyei-Manu W,Langer R,Farokhzad OC. Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett 2008; 8:2906-12. PubMed
  • Levy-Nissenbaum E,Radovic-Moreno AF,Wang AZ,Langer R,Farokhzad OC. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008; 26:442-9. PubMed
  • Zhang L,Chan JM,Gu FX,Rhee JW,Wang AZ,Radovic-Moreno AF,Alexis F,Langer R,Farokhzad OC. Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2009; 2:1696-702. PubMed
  • Wang AZ,Gu F,Zhang L,Chan JM,Radovic-Moreno A,Shaikh MR,Farokhzad OC. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 2008; 8:1063-70. PubMed
  • Alexis F,Pridgen E,Molnar LK,Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 2008; 5:505-15. PubMed
  • Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 2007; 83:761-9. PubMed
  • Teply BA, Tong R, Jeong SY, Luther G, Sherifi I, Yim CH, Khademhosseini A, Farokhzad OC, Langer RS, Cheng J. The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. Biomaterials 2007; 29:1216-23. PubMed
  • Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, Langer R, Farokhzad OC. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A 2008; 105:2586-91. PubMed
  • Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urol Oncol 2008; 26:74-85. PubMed
  • Peer D,Karp JM,Hong S,Farokhzad OC,Margalit R,Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2008; 2:751-60. PubMed
  • Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, Farokhzad OC. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007; 7:3065-70. PubMed
  • Pridgen EM, Langer R, Farokhzad OC. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomed 2007; 2:669-80. PubMed
  • Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, Jon S, Langer RS, Farokhzad OC. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007; 2:1268-71. PubMed
  • Park H, Cannizzaro C, Vunjak-Novakovic G, Langer R, Vacanti CA, Farokhzad OC. Nanofabrication and Microfabrication of Functional Materials for Tissue Engineering. Tissue Eng 2007; 13:1867-77. PubMed
  • Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2006; 28:869-76. PubMed
  • Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 2006; 45:8149-52. PubMed
  • Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev 2006; 58:1456-9. PubMed
  • Farokhzad OC, Dimitrakov JD, Karp JM, Khademhosseini A, Freeman MR, Langer R. Drug delivery systems in urology--getting "smarter". Urology 2006; 68:463-9. PubMed
  • Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 2006; 3:311-24. PubMed
  • Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006; 103:6315-20. PubMed
  • Cheng J, Teply BA, Jeong SY, Yim CH, Ho D, Sherifi I, Jon S, Farokhzad OC, Khademhosseini A, Langer RS. Magnetically responsive polymeric microparticles for oral delivery of protein drugs. Pharm Res 2006; 23:557-64. PubMed
  • Fukuda J, Khademhosseini A, Yeh J, Eng G, Cheng J, Farokhzad OC, Langer R. Micropatterned cell co-cultures using layer-by-layer deposition of extracellular matrix components. Biomaterials 2005; 27:1479-86. PubMed
  • Khademhosseini A, Yeh J, Eng G, Karp J, Kaji H, Borenstein J, Farokhzad OC, Langer R. Cell docking inside microwells within reversibly sealed microfluidic channels for fabricating multiphenotype cell arrays. Lab Chip 2005; 5:1380-6. PubMed
  • Farokhzad OC, Khademhosseini A, Jon S, Hermmann A, Cheng J, Chin C, Kiselyuk A, Teply B, Eng G, Langer R. Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal Chem 2005; 77:5453-9. PubMed
  • Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004; 64:7668-72. PubMed
  • Nicolaou F, Teodoridis JM, Park H, Georgakis A, Farokhzad OC, B. CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD. Blood 2003; 101:4033-41. PubMed
  • Shelley CS, Teodoridis JM, Park H, Farokhzad OC, B. During differentiation of the monocytic cell line U937, Pur alpha mediates induction of the CD11c beta 2 integrin gene promoter. J Immunol 2002; 168:3887-93. PubMed
  • Song JC, Hanson CM, Tsai V, Farokhzad OC, Lotz M, Matthews JB. Regulation of epithelial transport and barrier function by distinct protein kinase C isoforms. Am J Physiol Cell Physiol 2001; 281:C649-61. PubMed
  • Farokhzad OC, Teodoridis JM, Park H, Arnaout MA, Shelley CS. CD43 gene expression is mediated by a nuclear factor which binds pyrimidine-rich single-stranded DNA. Nucleic Acids Res 2000; 28:2256-67. PubMed
  • Song JC, Hrnjez BJ, Farokhzad OC, Matthews JB. PKC-epsilon regulates basolateral endocytosis in human T84 intestinal epithelia: role of F-actin and MARCKS. Am J Physiol 1999; 277:C1239-49. PubMed
  • Farokhzad OC, Sagar GD, Mun EC, Sicklick JK, Lotz M, Smith JA, Song JC, O'Brien TC, Sharma CP, Kinane TB, Hodin RA, Matthews JB. Protein kinase C activation downregulates the expression and function of the basolateral Na+/K+/2Cl(-) cotransporter. J Cell Physiol 1999; 181:489-98. PubMed
  • Farokhzad OC, Mun EC, Sicklick JK, Smith JA, Matthews JB. Effects of bryostatin 1, a novel anticancer agent, on intestinal transport and barrier function: role of protein kinase C. Surgery 1998; 124:380-6; discussion 386-7. PubMed
  • Mun EC, Mayol JM, Riegler M, O'Brien TC, Farokhzad OC, Song JC, Pothoulakis C, Hrnjez BJ, Matthews JB. Levamisole inhibits intestinal Cl- secretion via basolateral K+ channel blockade. Gastroenterology 1998; 114:1257-67. PubMed
  • Farokhzad OC, Shelley CS, Arnaout MA. Induction of the CD11b gene during activation of the monocytic cell line U937 requires a novel nuclear factor MS-2. J Immunol 1996; 157:5597-605. PubMed
  • B. The human beta 2 integrin CD18 promoter consists of two inverted Ets cis elements. Mol Cell Biol 1994; 14:2604-15. PubMed
  • Shelley CS, Farokhzad OC, Arnaout MA. Identification of cell-specific and developmentally regulated nuclear factors that direct myeloid and lymphoid expression of the CD11a gene. Proc Natl Acad Sci U S A 1993; 90:5364-8. PubMed
Hide